Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.
Marco Falcone,Giusy Tiseo,Beatrice Valoriani,Chiara Barbieri,Sara Occhineri,Paola Mazzetti,Maria Linda Vatteroni,Lorenzo Roberto Suardi,Niccolò Riccardi,Mauro Pistello,Danilo Tacconi,Francesco Menichetti +11 more
TLDR
In this paper, the risk of hospitalization or death in patients infected by SARS-CoV2 variants of concern (VOCs) receiving combinations of monoclonal antibodies (mAbs), bamlanivimab/etesevimab or casirivimabel/imdevimab was evaluated.Abstract:
The aim of this study was to evaluate the risk of hospitalization or death in patients infected by SARS-CoV2 variants of concern (VOCs) receiving combinations of monoclonal antibodies (mAbs), bamlanivimab/etesevimab or casirivimab/imdevimab. Observational prospective study conducted in two Italian hospitals (University Hospital of Pisa and San Donato Hospital, Arezzo) including consecutive outpatients with COVID-19 who received bamlanivimab/etesevimab or casirivimab/imdevimab from March 20th to May 10th 2021. All patients were at high risk of COVID-19 progression according to FDA/AIFA recommendations. Patients were divided into two study groups according to the infecting viral strain (VOCs): Alpha and Gamma group. The primary endpoint was a composite of hospitalization or death within 30 days from mAbs infusion. A Cox regression multivariate analysis was performed to identify factors associated with the primary outcome in the overall population. The study included 165 patients: 105 were infected by the VOC Alpha and 43 by the VOC Gamma. In the Alpha group, no differences in the primary endpoint were observed between patients treated with bamlanivimab/etesevimab or casirivimab/imdevimab. Conversely, in the Gamma group, a higher proportion of patients treated with bamlanivimab/etesevimab met the primary endpoint compared to those receiving casirivimab/imdevimab (55% vs. 17.4%, p = 0.013). On multivariate Cox-regression analysis, the Gamma variant and days from symptoms onset to mAbs infusion were factors independently associated with higher risk of hospitalization or death, while casirivimab/imdevimab was protective (HR 0.33, 95% CI 0.13–0.83, p = 0.019). In patients infected by the SARS-CoV-2 Gamma variant, bamlanivimab/etesevimab should be used with caution because of the high risk of disease progression.read more
Citations
More filters
Journal ArticleDOI
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Rekha Khandia,Shailja Singhal,Taha Alqahtani,Mohammad Amjad Kamal,Nahed A. El-Shall,Firzan Nainu,P. A. Desingu,Kuldeep Dhama +7 more
TL;DR: The most recently emerged variant of concern (VOC) is the Omicron (B.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies as mentioned in this paper .
Journal ArticleDOI
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Manish Dhawan,AbdulRahman A. Saied,Saikat Mitra,Fahad A. Alhumaydhi,Talha Bin Emran,Polrat Wilairatana +5 more
TL;DR: The Omicron variant has been identified as a highly modified, contagious, and crucial variant among the five VOCs of SARS-CoV-2 in the COVID-19 pandemic as mentioned in this paper .
Journal ArticleDOI
Therapeutic monoclonal antibodies for COVID-19 management: an update
Vivek P. Chavda,Riddhi Prajapati,Disha Lathigara,Bhumi Nagar,Jay Kukadiya,Elrashdy M. Redwan,Vladimir N. Uversky,Mukesh N. Kher,Patel Rajvi +8 more
TL;DR: This review article provides insights into the basic aspects of monoclonal antibodies for the therapy of COVID-19, as well as its advancement in terms of clinical trial and current approval status.
Journal ArticleDOI
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
David T. Huang,Erin K McCreary,J. Ryan Bariola,Tami Minnier,Richard J. Wadas,Judith A Shovel,D. Albin,Oscar C. Marroquin,Kevin E. Kip,Kevin Collins,Mark Schmidhofer,Mary Kay Wisniewski,David A. Nace,C. Sullivan,M. Axe,R. Meyers,Alexandra Weissman,WilliamF. Garrard,Octavia M Peck-Palmer,Alan Wells,Robert D. Bart,Anne Yang,Lindsay R. Berry,Scott M. Berry,Amy Crawford,Anna McGlothlin,Tina Khadem,Kelsey Linstrum,Stephanie K. Montgomery,Daniel Ricketts,Jason Kennedy,Caroline Pidro,Anna Nakayama,Rachel L. Zapf,P. L. Kip,Ghady Haidar,Graham M. Snyder,Bryan J. McVerry,Donald M. Yealy,Derek C. Angus,Christopher W. Seymour +40 more
TL;DR: In this paper , the authors evaluated the effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant.
Journal ArticleDOI
Caring for older adults during the COVID-19 pandemic
TL;DR: A literature review for studies on COVID-19 in elderly patients published between December 2019 and November 2021 was performed as mentioned in this paper , which highlighted peculiar aspects of elderly patients and factors contributing to high risk of poor outcome in this category.
References
More filters
Journal ArticleDOI
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Delphine Planas,David Veyer,Artem Baidaliuk,Isabelle Staropoli,Florence Guivel-Benhassine,Maaran Michael Rajah,Maaran Michael Rajah,Cyril Planchais,Françoise Porrot,Nicolas Robillard,Julien Puech,Matthieu Prot,Floriane Gallais,Pierre Gantner,Aurélie Velay,Julien Le Guen,Najiby Kassis-Chikhani,Dhiaeddine Edriss,Laurent Bélec,Aymeric Sève,Laura Courtellemont,Hélène Péré,Laurent Hocqueloux,Samira Fafi-Kremer,Thierry Prazuck,Hugo Mouquet,Timothée Bruel,Etienne Simon-Loriere,Félix A. Rey,Olivier Schwartz +29 more
TL;DR: In this paper, an infectious strain of the SARS-CoV-2 Delta variant was isolated from an individual with COVID-19 who had returned to France from India.
Journal ArticleDOI
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
David M. Weinreich,Sumathi Sivapalasingam,Thomas Norton,Shazia Ali,Haitao Gao,Rafia Bhore,Bret J Musser,Yuhwen Soo,Diana Rofail,Joseph Im,Christina Perry,Cynthia Pan,Romana Hosain,Adnan Mahmood,John D. Davis,Kenneth C. Turner,Andrea T. Hooper,Jennifer D. Hamilton,Alina Baum,Christos A. Kyratsous,Yunji Kim,Amanda Cook,Wendy Kampman,Anita Kohli,Yessica Sachdeva,Ximena Graber,Bari Kowal,Thomas DiCioccio,Neil Stahl,Leah Lipsich,Ned Braunstein,Gary Herman,George D. Yancopoulos +32 more
TL;DR: In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.
Journal ArticleDOI
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Markus Hoffmann,Markus Hoffmann,Prerna Arora,Prerna Arora,Rüdiger Groß,Alina Seidel,Bojan F. Hörnich,Alexander S. Hahn,Nadine Krüger,Luise Graichen,Heike Hofmann-Winkler,Amy Kempf,Amy Kempf,Martin Sebastian Winkler,Sebastian R. Schulz,Hans-Martin Jäck,Bernd Jahrsdörfer,Bernd Jahrsdörfer,Hubert Schrezenmeier,Hubert Schrezenmeier,Martin Müller,Alexander Kleger,Jan Münch,Stefan Pöhlmann,Stefan Pöhlmann +24 more
TL;DR: In this article, the authors show that SARS-CoV-2/COVID-19 variants B.1.7 (UK), B.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies.
Journal ArticleDOI
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Robert L. Gottlieb,Ajay Nirula,Peter Chen,Joseph Boscia,Barry Heller,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Princy Kumar,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Timothy R. Holzer,Philip J. Ebert,Richard E. Higgs,Nicole L. Kallewaard,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Lei Shen,Daniel Skovronsky +26 more
TL;DR: The BLAZE-1 trial as mentioned in this paper evaluated the effect of bamlanivimab monotherapy and combination therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.
Journal ArticleDOI
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.
Pengfei Wang,Ryan G. Casner,Manoj S. Nair,Maple Wang,Jian Yu,Gabriele Cerutti,Lihong Liu,Peter D. Kwong,Yaoxing Huang,Lawrence Shapiro,Lawrence Shapiro,David D. Ho,David D. Ho +12 more
TL;DR: The P.1 trimer adopts exclusively a conformation in which one of the receptor-binding domains is in the "up" position, which is known to facilitate binding to the entry receptor ACE2.
Related Papers (5)
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Astrid Lièvre,Anthony Turpin,Isabelle Ray-Coquard,Karine Le Malicot,Juliette Thariat,Guido Ahle,Cindy Neuzillet,Xavier Paoletti,Olivier Bouché,Kais Aldabbagh,Pierre Michel,Didier Debieuvre,Anthony Canellas,M. Wislez,Lucie Laurent,May Mabro,Raphael Colle,Anne-Claire Hardy-Bessard,Laura Mansi,Emeline Colomba,Jean Bourhis,Philippe Gorphe,Yoann Pointreau,Ahmed Idbaih,Renata Ursu,Anna Luisa Di Stefano,Gérard Zalcman,Thomas Aparicio,investigators +28 more